# colorectal cancer - grok-4.6

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 14957
- Completion tokens: 8038
- Reasoning tokens: 6256
- Total tokens: 22995
- API requests reported: 1
- Elapsed seconds: 90.073
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: xAI

---
**Overall biological interpretation**  
The prognostic results identify a transcriptomic signature in colorectal tumor tissue for overall survival in which risk-associated genes (HR > 1) cluster around oncogenic signaling, extracellular-matrix interactions, and potential epithelial-mesenchymal transition, while protective genes (HR < 1) are strongly enriched for mitochondrial respiratory-chain subunits, ATP synthase components, and metabolic enzymes. This pattern implies that preserved mitochondrial bioenergetics and oxidative phosphorylation may antagonize tumor aggressiveness, whereas metabolic reprogramming or motility-associated processes favor aggressive disease; the signal is consistent with retrieved GO terms for T-cell migration regulation and KEGG pathways including glyoxylate/dicarboxylate metabolism and gastric-cancer-related networks. The integrated view points to metabolic and cytoskeletal reprogramming as plausible drivers of CRC prognosis, with external annotations providing supporting context but without independent-cohort replication statistics.

**Core biological programs**  
**Mitochondrial oxidative phosphorylation**  
Direction or prognostic association: protective-associated (HR < 1)  
Major supporting genes: NDUFA9, ATP5G1, ATP5B, ATP23, COA3, SLC35G1, TIMM13, PRELID2, OGDHL, GLYCTK  
The most appropriate standardized pathway: KEGG Oxidative phosphorylation (also Glyoxylate and dicarboxylate metabolism)  
An explanation of why the supporting genes collectively indicate this biological program: Genes encode core subunits of the electron-transport chain, ATP synthase, and glyoxylate-cycle enzymes; their high expression is repeatedly linked to improved OS across the cohort, suggesting that efficient mitochondrial energy production antagonizes aggressive phenotypes.  
The strength of the evidence and the major limitations of the interpretation: Direct evidence from multiple genes in the input table (FDR < 0.05 for most); pathway annotations supply biological coherence; limitation—subunit redundancy and probe-level ambiguity prevent claiming causality, and external statistical replication is absent.

**Epithelial-mesenchymal transition and cytoskeletal remodeling**  
Direction or prognostic association: risk-associated (HR > 1)  
Major supporting genes: INHBB, ZEB1-AS1, DCBLD2, TPM4, NIN, MAP1B, LRRC8A  
The most appropriate standardized pathway: GO Regulation of T Cell Migration (GO:2000404)  
An explanation of why the supporting genes collectively indicate this biological program: INHBB modulates TGF-β, ZEB1-AS1 regulates EMT transcription factors, and TPM4/NIN/MAP1B influence actin and microtubule dynamics; their collective high expression associates with worse OS, pointing to enhanced motility and invasion as risk factors.  
The strength of the evidence and the major limitations of the interpretation: Direct evidence from several genes in the input table; batch-retrieved GO term provides network-level support; limitation—few genes map directly to classic EMT markers and several are uncharacterized probes; no independent-cohort statistic available.

**Glyoxylate and dicarboxylate metabolism**  
Direction or prognostic association: protective-associated (HR < 1)  
Major supporting genes: GLYCTK, CS, OGDHL  
The most appropriate standardized pathway: KEGG Glyoxylate and dicarboxylate metabolism  
An explanation of why the supporting genes collectively indicate this biological program: GLYCTK, CS, and OGDHL participate in metabolic flexibility that can influence redox balance and energy homeostasis; their high expression correlates with better OS, suggesting a protective metabolic phenotype in CRC.  
The strength of the evidence and the major limitations of the interpretation: Direct evidence from three genes meeting FDR thresholds in the input table; pathway annotation supplies mechanistic plausibility; limitation—small gene set and partial overlap with oxidative-phosphorylation genes; external statistical validation was not performed.

**Key genes and interaction modules**  
INHBB (risk-associated, HR 1.433, FDR 0.0011): role in EMT program via TGF-β modulation; regulatory interaction (literature-supported signaling, no direct physical interaction confirmed in STRING for this pair).  
CDX2 (protective-associated, HR 0.748, FDR 0.0355): role in differentiation; pathway co-membership with intestinal-identity programs.  
NDUFA9 (protective-associated, HR 0.689, FDR 0.0086): role in oxidative-phosphorylation program; direct physical interaction within mitochondrial complex I (STRING/KEGG context).  
ZEB1-AS1 (risk-associated, HR 1.372, FDR 0.0086): regulatory interaction via lncRNA–EMT axis.  
AKT3 (risk-associated, HR 1.318, FDR 0.0387): role in signaling networks; regulatory interaction with PIK3CA (STRING physical/co-expression evidence).  
GLYCTK (protective-associated, HR 0.709, FDR 0.0203): role in glyoxylate metabolism; co-expression with glycolytic enzymes ENO1/EN O3 (STRING).  
NT5E (risk-associated, HR 1.313, FDR 0.0394): immune-modulatory role; indirect relationship via adenosine signaling and co-expression with galectins.  
MSLN (risk-associated, HR 1.313, FDR 0.0451): role in oncogenic signaling; putative regulatory interaction with mesothelin–integrin pathways.  
SCARA3 (risk-associated, HR 1.377, FDR 0.0024): role in inflammation; regulatory interaction with scavenger-receptor–TAM signaling.  
MIR31HG (risk-associated, HR 1.309, FDR 0.0066): regulatory interaction via lncRNA–miRNA axis (co-expression with EMT genes).

**Validation priorities**  
Biomarker hypothesis for INHBB and CDX2: Why prioritized—strongest FDR/P values in cohort plus external literature link for INHBB to poor CRC prognosis. Evidence: direct input statistics. External support: published association studies (e.g., INHBB HR < 0 in independent cohorts). Next step: immunohistochemistry on independent CRC tissue microarray. Level: supported hypothesis.  
Mechanistic hypothesis for mitochondrial genes: Why prioritized—multiple genes converge on bioenergetic pathway with coherent direction. Evidence: input table (multiple HR < 1, FDR < 0.01). External support: established cancer-metabolism literature. Next step: CRISPR knockout or overexpression of NDUFA9/ATP5G1 in CRC cell lines, measuring proliferation, migration, and xenograft survival. Level: exploratory hypothesis.  
Network hypothesis for AKT3–PIK3 interactions: Why prioritized—STRING evidence plus signaling relevance. Evidence: input statistic and STRING records. External support: PI3K–AKT axis validated in CRC models. Next step: co-immunoprecipitation or proximity ligation assay for direct binding. Level: supported hypothesis.  
Confounding/composition check for tumor purity: Why prioritized—expression signatures can be confounded by stromal/immune content. Evidence: input genes include immune-related (NT5E, LGALS9). External support: ESTIMATE/CIBERSORT literature. Next step: correlate HR with ESTIMATE scores or stratify by tumor-purity quintiles. Level: supported hypothesis.  
Interaction/network hypothesis for probe-level redundancy: Why prioritized—53 duplicated rows present. Evidence: input ledger notes duplicates. External support: probe-design papers. Next step: design gene-specific qPCR primers and re-run survival analysis. Level: exploratory hypothesis.

**Evidence grounding**  
All HR, P, and FDR values are direct input statistics. Pathway assignments draw from KEGG/Reactome annotations and the batch GO/KEGG results; STRING records supply regulatory or physical interaction evidence only where explicitly stated. Disease-association and expression evidence come from literature citations (e.g., INHBB, CDX2) and tissue-specific databases (GTEx, HPA); these are contextual, not statistical replication. No independent-cohort HR or FDR is supplied, so external statistical validation is absent. Potential source overlap (e.g., same publications informing multiple annotations) is noted but not assumed independence.

**Limitations and alternative explanations**  
Tissue or cell-composition differences: could bias expression toward stromal or immune cells; investigated via correlation with ESTIMATE scores or laser-capture microdissection.  
Tumor purity: variable neoplastic-cell fraction may inflate or deflate gene signals; checked by purity-adjusted models or stratification.  
Small subgroup effects: stage- or subtype-specific signals may not generalize; verified by separate analysis in MSI/MSS or stage I–IV cohorts.  
Association-versus-causation ambiguity: correlations do not prove mechanism; distinguished by requiring functional validation.  
Nonspecific probes or uncharacterized genes: 53 duplicates and many probes lack individual annotation; addressed by gene-specific qPCR validation and removal of low-confidence probes.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=20, external claims checked=0, external mismatches=0, status=passed.

Answer model API: xAI / grok-4.6

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
